Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharmas Among Biggest Cash Hoarders, Moody’s Finds

This article was originally published in The Pink Sheet Daily

Executive Summary

A Moody’s report lists seven pharmas among the 50 non-financial companies sitting on the largest piles of cash. These very big war chests hold the preferred currency, particularly for ex-U.S.pharma deal-making.

Advertisement

Related Content

Deals of the Week Takes Stock In M&A
Licensing Deals Still Backloaded In 2013, But Biotechs Could Gain Leverage
U.S. Pharmas Rank 2nd To Tech Sector In Cash, But Spend It Differently, Moody’s Says
Biopharma Tax Strategy Demystified: A Q&A With Ernst & Young
Financings Of The Fortnight: Overseas Cash Holdings Don’t Mean U.S. Biopharma Lacks For Domestic Financial Opportunity
Deals Of The Week Untangles The String Of Pearls
Pfizer Sells Nutrition Portfolio To Nestle For Nearly $12B
Amgen Gobbles Up Micromet In $1.16 Billion BiTE
J&J Renews Commitment To Devices With Synthes Deal
A Goliath Grows: Pfizer Buys Wyeth For $68 Billion

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS075426

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel